Dateline City:
WHITEHOUSE STATION, N.J.
2013 First-Quarter Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.52
Worldwide Sales were $10.7 Billion, a Decrease of 9 Percent Primarily as a Result of Patent Expiries, and Including a 2 Percent Unfavorable Impact from Foreign Exchange
Growth in Vaccines, Immunology, HIV, Animal Health and Consumer Care Products
Received Breakthrough Therapy Designation for Lambrolizumab, an Investigational Candidate for Advanced Melanoma; Five Products Currently Under Regulatory Review
Announced New $15 Billion Share Repurchase Program; Plans to Repurchase Approximately $7.5 Billion of Common Stock over the Next Twelve Months
Revises 2013 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Revises GAAP EPS Range to $1.92 to $2.16
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced financial results for the first quarter of 2013.
$ in millions, except EPS amounts
FirstQuarter2013
FirstQuarter2012
Language:
English
Contact HTML:
MerckMedia Contacts:Steve Cragle, 908-423-3461Kelley Dougherty, 908-423-4291orInvestor Contacts:Carol Ferguson, 908-423-4465Alex Kelly, 908-423-5185
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more